What MK-677 does: the mechanism
MK-677 (ibutamoren mesylate) is an orally active, non-peptide growth hormone secretagogue. It mimics ghrelin — the hunger hormone — by binding to the ghrelin receptor (GHS-R1a), which stimulates the pituitary gland to release growth hormone (GH). Unlike exogenous GH injection, MK-677 works through the body's own regulatory feedback loop, producing pulsatile GH release that more closely resembles physiological patterns[1].
The downstream effect that most users care about is elevated IGF-1 (insulin-like growth factor 1). GH stimulates the liver to produce IGF-1, which mediates most of the anabolic, recovery, and tissue-repair effects attributed to growth hormone. MK-677 sustains elevated GH and IGF-1 for 24 hours from a single oral dose[2].
IGF-1: the primary target marker
MK-677 at the standard dose of 25 mg/day typically raises IGF-1 by 40-90% from baseline. In a pivotal study by Murphy et al., healthy young men saw IGF-1 rise from approximately 200 ng/mL to 350 ng/mL within two weeks[2]. In elderly subjects, Nass et al. demonstrated that 25 mg/day for 2 years increased IGF-1 to levels seen in healthy young adults[3].
IGF-1 levels typically plateau within 2-4 weeks. The increase is sustained for as long as the compound is used and returns to baseline within 2-4 weeks of discontinuation.
What to watch for: IGF-1 levels above 400 ng/mL in adults are generally considered supraphysiological. Chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies[4]. If your IGF-1 exceeds 350-400 ng/mL, consider reducing dose or discontinuing.
Glucose and insulin: the metabolic cost
This is the most clinically important side effect of MK-677. Growth hormone is a counter-regulatory hormone to insulin — it opposes insulin's action on glucose disposal. By raising GH, MK-677 predictably impairs insulin sensitivity and raises fasting blood glucose[5].
In the 2-year Nass et al. trial, fasting glucose increased by approximately 5-10 mg/dL on average, and some subjects progressed to impaired fasting glucose (>100 mg/dL). Fasting insulin also rose, indicating the pancreas was working harder to maintain glucose control[3].
In a study of obese subjects, MK-677 worsened insulin sensitivity as measured by HOMA-IR, with some subjects developing frankly diabetic glucose levels[6].
| Marker | Expected change | When to test | Red flag |
|---|---|---|---|
| IGF-1 | +40-90% | Baseline, 4 weeks, then quarterly | >400 ng/mL sustained |
| Fasting glucose | +5-10 mg/dL | Baseline, 4 weeks, then quarterly | >100 mg/dL |
| Fasting insulin | +20-50% | Baseline, 4 weeks, then quarterly | >15 mIU/L |
| HbA1c | +0.1-0.3% | Baseline, 3 months | >5.7% |
| Prolactin | +10-20% (transient) | Baseline, 4 weeks | >25 ng/mL (men) |
| Cortisol (AM) | +10-20% (transient) | Baseline, 4 weeks | Persistent elevation |
Prolactin: usually minor, worth tracking
MK-677 can cause a modest, transient rise in prolactin. The mechanism is likely indirect — ghrelin receptor activation in the hypothalamus can modestly stimulate prolactin release. In most clinical trials, prolactin increases were small (10-20% above baseline) and tended to normalize within weeks despite continued use[7].
However, individuals who are stacking MK-677 with other compounds that raise prolactin (certain anabolic steroids, for example) should be aware of the additive effect. Symptoms of clinically elevated prolactin in men include decreased libido, erectile dysfunction, and gynecomastia.
Cortisol: the transient spike
MK-677 acutely increases cortisol secretion, particularly in the first few weeks of use. This is a direct effect of ghrelin receptor activation on the hypothalamic-pituitary-adrenal (HPA) axis. In the Murphy et al. study, 24-hour cortisol AUC increased by approximately 20% initially but returned to near-baseline levels by 2-4 weeks of continued use[2].
The cortisol elevation is generally self-limiting. However, individuals with pre-existing elevated cortisol (Cushing's, chronic stress, high-dose glucocorticoid use) should monitor this marker early in use[8].
Other effects on blood work
Thyroid function
MK-677 has been reported to cause a modest decrease in T4 and T3 in some studies, likely through GH-mediated effects on thyroid hormone metabolism. The clinical significance is unclear, but a thyroid panel at baseline and 3 months is reasonable[9].
Lipid panel
Data on MK-677 and lipids is limited. Some studies show no significant effect; others report modest increases in LDL. A baseline lipid panel and follow-up at 3 months is sufficient for most users.
Practical monitoring protocol
- Before starting: Get baseline IGF-1, fasting glucose, fasting insulin (or HOMA-IR), HbA1c, prolactin, AM cortisol, thyroid panel (TSH, free T4, free T3), comprehensive metabolic panel, and lipid panel.
- At 4-6 weeks: Retest IGF-1, fasting glucose, fasting insulin, prolactin, and cortisol. This is when most metabolic effects are established and prolactin/cortisol should be normalizing.
- Every 3 months during use: IGF-1, fasting glucose, fasting insulin, HbA1c. Add thyroid and lipids annually.
- Stop or reduce dose if: fasting glucose exceeds 100 mg/dL, HbA1c exceeds 5.7%, IGF-1 exceeds 400 ng/mL, or prolactin becomes symptomatic[10].